Loading
A phase 2/3 trial of Darovasertib, Crizotinib, Pembrolizumab in melanoma and uveal melanoma, run by IDEAYA Biosciences, active and no longer recruiting.
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma is a phase 2/3 interventional study registered as NCT05987332 by IDEAYA Biosciences, with 420 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-01-15. Interventions recorded: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab. Conditions listed: Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma, Melanoma.
Shares Darovasertib, IDEAYA Biosciences, Crizotinib, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Uveal melanoma, Ipilimumab, Nivolumab, Melanoma.
Shares Darovasertib, Uveal melanoma, Melanoma.
Shares Uveal melanoma, Ipilimumab, Melanoma, Pembrolizumab.
Shares Ipilimumab, Nivolumab, Melanoma, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/